Cassava Sciences (NASDAQ: SAVA)
Cassava Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cassava Sciences Company Info
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
News & Analysis
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.
Why Cassava Sciences Stock Is Skyrocketing Today
Investors liked what Cassava's new executive chairman had to say.
Why Cassava Sciences Stock Is Sinking Today
The biotech stock is feeling the heat from an indictment of a former consultant.
Is There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper.
Why Cassava Sciences Stock Zoomed 21% Higher This Week
The company chooses an offbeat way to keep its investors sweet.
Why Cassava Sciences Stock Soared Today
Investors cheered the arrival of a trio of new board members.
1 Big Red Flag to Fear When a Stock Is Down
Playing the blame game does not make for an effective turnaround strategy.
Why Cassava Sciences Stock Is Tanking Today
Investors are worried about a leaked report related to alleged data manipulation for Cassava's Alzheimer's disease treatment candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.